Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Supernus Pharmaceuticals, Inc. (SUPN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
35.51+1.65 (+4.87%)
At close: 04:00PM EDT
35.51 0.00 (0.00%)
After hours: 04:27PM EDT
Advertisement

Supernus Pharmaceuticals, Inc.

9715 Key West Avenue
Rockville, MD 20850
United States
301 838 2500
https://www.supernus.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees603

Key Executives

NameTitlePayExercisedYear Born
Mr. Jack A. KhattarFounder, Pres, CEO, Sec. & Director1.78MN/A1961
Mr. Timothy C. DecSr. VP & CFO457.62kN/A1959
Dr. Padmanabh P. BhattChief Scientific Officer & Sr. VP of Intellectual Property598.61kN/A1957
Ms. Tami T. MartinSr. VP of Regulatory Affairs508.5k112.52k1955
Dr. Jonathan RubinSr. VP of R&D and Chief Medical Officer557.7kN/A1961
Mr. Kevin T. AndersonCompliance OfficerN/AN/A1962
Dr. Todd Horich M.B.A., Ph.D.Sr. VP of Marketing & Market AccessN/AN/AN/A
Mr. Taylor RaifordSr. VP of SalesN/AN/AN/A
Dr. Bryan A. Roecklein Ph.D.Sr. VP of Corp. Devel.N/AN/AN/A
Mr. Frank MottolaSr. VP of Quality, GMP Operations & Information TechnologyN/AN/A1972
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Corporate Governance

Supernus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 5. The pillar scores are Audit: 9; Board: 3; Shareholder Rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement